Alnylam (ALNY) Canada announced that OXLUMO is now funded across Canada through both public and private plans. OXLUMO is an RNA interference therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma’s Amvuttra
- Alnylam’s NeuroFeeL Study: A New Frontier in Amyloidosis Biomarker Research
- Alnylam price target raised to $377 from $320 at Needham
- Alnylam Pharma’s Promising Outlook: Analyst Joseph Stringer Raises Price Target Amid Optimism for Amvuttra Launch
- Alnylam’s NeuroFeeL Study: A New Frontier in Biomarker Research